Travere Therapeutics spent the first half of 2026 converting a single approved medicine into a broader commercial and pipeline story. A rare-disease drugmaker built around FILSPARI, its treatment for ...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the focal segmental ...

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on Insmed, with a price target of $207.00. Claim 55% Off TipRanks. Unlock powerful investing tools ...

NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, ...

Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zura Bio , Insmed and Harmony Biosciences Holdings . TipRanks Welcomes a New ETF ...

Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.

With its focus on small-cap companies and exposure to China, The Biotech Growth Trust (BIOG) is one such example. Over the past year, the trust’s total shareholder return was 105 per cent – double the ...

With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3 testing, ...